California-based Azalea Therapeutics, a biotech promising to redefine precision genomic medicines in vivo, has announced its ...
Genetically modified organisms, also known as GMOs, have been a hot topic of conversation among researchers, producers, ...
To add to its globally leading universities, London’s competitive advantages in frontier innovation also include its deep and ...
NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...
Smith, a microbiologist whose discovery revolutionize the field of genetic engineering, was a Johns Hopkins School of ...
Key market opportunities for Cas12 proteins include rising government investments in biotech, increased demand for ...
In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...
It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.
According to Nova One Advisor, the global gene editing market size is calculated at USD 11.29 billion in 2025 and is expected ...
Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...
According to Bloomberg News, Vinay Prasad, who oversees gene therapies at the FDA, said the plans will be published in early November. He foresees the approach sparking curiosity for the next wave of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback